Why This Stock Could Double Your Money in 2022
The past year hasn't been great for Axsome Therapeutics (NASDAQ: AXSM). Shares of the company are down by about 24% in the trailing 12-month period. Given this recent poor performance, it could be hard to believe that Axsome has the tools to turn things around.
However, this biotech has several catalysts that could send its stock price soaring. Axsome's average price target currently stands at about $81, according to Yahoo! Finance, which is almost double its current stock price of $41. Let's consider why this biotech could live up to the Street's expectations even before the year comes to a close.
Image source: Getty Images.
Source Fool.com
